Brief: Lipidor And Cannassure Enter Feasibility Study And Licence Option Agreement For Development And Sales Of Topical Medical Cannabis Products
10/12/2019 07:29
Dec 10 (Reuters) - Lipidor AB LIPI.ST :
* LIPIDOR (NASDAQ FIRST NORTH: LIPI) AND CANNASSURE
(TASE:CSURE)
ENTER A FEASIBILITY STUDY AND LICENCE OPTION AGREEMENT FOR
DEVELOPMENT AND SALES OF TOPICAL MEDICAL CANNABIS PRODUCTS
* FEASIBILITY STUDY IS EXPECTED TO CONCLUDE IN Q3 2020
* ACCORDING TO AN IMARC GROUP REPORT, GLOBAL MARKET FOR
MEDICAL
CANNABIS IS EXPECTED TO REACH 44 BN USD IN 2024
* JOINT AMBITION IS TO INTRODUCE INNOVATIVE PRODUCTS FOR
TOPICAL
TREATMENTS ON FAST-GROWING GLOBAL MARKET FOR MEDICAL CANNABIS
Source text for Eikon: ID:nWkr58Bbx6
Further company coverage: LIPI.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))